Details

To obtain approval, the importer must confirm that the medicinal product meets the criteria of Article 78 of the Law. In particular, when assessing identity or similarity, the active substances, form, dosage, indications, and route of administration are compared. 45 calendar days are allowed for the decision, and this period can be suspended for clarifications, and the applicant pays for the review of the dossier by the State Expert Center under the contract.

The first decisions showed what issues arise during the review. In November 2023, the regulatory authority rejected two applications for meropenem due to an incomplete set of materials, an inconsistent method of placing the product on the market, and unconfirmed authority of the representative. In May 2026, two resubmitted applications for the same dosages were also rejected.

But even obtaining a permit does not guarantee sales. The law allows for the wholesale distribution of parallel-imported medicines, including supplies to hospitals and authorized purchasers. On the other hand, sales and dispensing through pharmacies are explicitly prohibited.

What's next

The current model has two significant limitations, and both are stipulated by law: a separate authorization for each drug and a ban on sales through pharmacies. They determine the cost of entry and the pool of available buyers, and this determines whether it will be profitable for the importer to supply medicines to Ukraine.

Firstly, the procedure already allows for changes in package sizes through amendments to the dossier. The next step could be the joint submission of materials and a single authorization for clearly defined dosages and package sizes of a single drug. In this case, compliance with the requirements shall be confirmed for each option separately, and identical documents shall be considered together.